The current study was conducted to further investigate the relationships among plasma Aß and clusterin levels, atrophy ratings determined by MRI assessment, and clinical symptoms in patients with AD and those with mild cognitive impairment (MCI). This evidence concerns the gene CLU and Alzheimer disease.